Regeneron Pharmaceuticals (REGN) announced a strategic collaboration with Truveta and its collective of U.S. health systems to advance innovation and data-driven discovery across the life sciences, public health and healthcare delivery ecosystem. Regeneron will provide a strategic investment of $119.5M as part of Truveta’s Series C financing round and collaborate with Truveta to launch the Truveta Genome Project. This project will extend Regeneron’s world-leading DNA sequence-linked healthcare database with an ambitious new effort to sequence up to ten million additional de-identified patient volunteers, all with linked electronic health records. This novel resource is designed to unlock profound insights into how genetics impact health and has the potential to ultimately lead to new genetic-based therapies and optimized healthcare services. Illumina (ILMN) will also invest $20M in Truveta’s Series C financing round in support of the Truveta Genome Project.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron price target lowered to $950 from $1,000 at Oppenheimer
- REGN LAWSUIT ALERT: Levi & Korsinsky LLP Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
- QQQ ETF News, 1/8/2025
- Regeneron price target lowered to $1,004 from $1,126 at Truist
- Regeneron price target lowered to $1,184 from $1,215 at RBC Capital